An Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics and Safety of JZP-110 in Subjects with Normal or Impaired Renal Function and with End-Stage Renal Disease Requiring Hemodialysis

Trial Profile

An Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics and Safety of JZP-110 in Subjects with Normal or Impaired Renal Function and with End-Stage Renal Disease Requiring Hemodialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Hypersomnia; Narcolepsy; Renal failure; Sleep apnoea syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 09 Jun 2017 Results presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
    • 09 Jun 2017 New trial record
    • 24 May 2017 According to a Jazz Pharmaceuticals plc media release, data from the study will be presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top